Single Cancer Vaccine or Set of Vaccines May Soon Cover Patient-Specific Mutations
Hospital leaders and oncologists should be aware of how cancer vaccine technology is developing and how it will be used to treat patient-specific tumors.
Hospital leaders and oncologists should be aware of how cancer vaccine technology is developing and how it will be used to treat patient-specific tumors.
A recent Georgetown cfDNA analysis study points to certain modifications to DNA, called methylations, that allow researchers to identify what type of cell the DNA came from. The review may set the stage for future research efforts.
This genetic breakthrough related to obsessive-compulsive disorder (OCD) will support the development of promising treatments for those who have not responded well to conventional treatments.
Studied in relation to neurodegenerative diseases, neurological disorders, and other elements of health and behavior, mitochondrial change is an important piece.
Notable for pediatric immunology specialists and hospitals that treat genetic conditions in infants and children, this genetic technology may allow full recovery for children with SCID, instead of a lifetime of medical monitoring and treatments.
Research now links human saliva proteins in a multitude of ways. With saliva signatures recognized by thousands of identifiable proteins, a new public database that catalogs and curates this data in relation to disease studies offers a promising resource for hospitals.
With a new Kidney Care Choices model starting January 1, 2022, hospital executives may be considering strategies, including precision medicine strategies.
A new 3D bio-printing method marks an exciting beginning to precision medicine treatments for highly-aggressive glioblastoma cancer.
Breast imagers are uniquely positioned to lead the way in AI cancer screening through their extensive experience with computer-assisted diagnosis (CAD), stated Constance Lehman, MD, PhD, a diagnostic radiologist, Professor of Radiology at Harvard Medical School, and Director of Breast Imaging at MGH.
Research will continue toward the value and medical necessity of both WES and WGS where results directly influence medical management and clinical outcomes. As a result, reimbursement for the uses of these testing methods may be changing as more about their roles is learned.